Voiant Medical

Voiant Medical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Voiant Medical is a specialized imaging CRO founded in 2018, headquartered in Salt Lake City, Utah. The company combines over 30 years of collective clinical trial imaging expertise with a proprietary AI-powered platform to accelerate the processing, analysis, and adjudication of medical images for clinical trials. It serves as a critical partner for biopharmaceutical companies, aiming to improve the speed and quality of imaging endpoint data to support regulatory submissions and drug approvals. With a track record of supporting over 700 trials and 70 drug approvals, Voiant positions itself as an industry leader in technology-enhanced clinical imaging services.

OncologyOphthalmologyRespiratory

Technology Platform

Purpose-built, AI-powered platform for clinical trial imaging processing, analysis, and endpoint adjudication. Integrates automation for image QC, segmentation, and measurement with oversight from subspecialty-trained clinical readers.

Opportunities

The growing complexity and use of imaging biomarkers in clinical trials, especially in oncology and ophthalmology, drives demand for specialized, tech-enabled CRO services.
The industry-wide push to accelerate drug development timelines creates a strong market for AI solutions that reduce imaging data turnaround times.

Risk Factors

Facing competition from larger, full-service CROs and niche imaging specialists.
Regulatory acceptance of AI-derived endpoints, while evolving, requires rigorous validation and poses a technology adoption risk.
Operational risks include maintaining quality across a global reader network.

Competitive Landscape

Competes with established imaging CROs like Clario (formerly BioClinica) and the imaging divisions of large CROs (ICON, Parexel, Labcorp). Differentiation is based on a dedicated AI platform, deep therapeutic expertise in key areas, and a claimed faster turnaround time. Also faces potential competition from pure-play AI imaging analytics companies.